Biodesp

Description

BiodespDMLabel is a pharmaceutical product characterized by its specific formulation and intended use. The product is designed for professional applications in the medical field, adhering to rigorous standards of quality and efficacy. Further details regarding its chemical composition, molecular weight, and dosage form are essential for healthcare professionals to understand its properties and applications in clinical settings.

Uses and Indications

This drug is indicated for the temporary relief of symptoms associated with the common cold, hay fever (allergic rhinitis), and other upper respiratory allergies. It is effective in alleviating cough due to minor throat and bronchial irritation. Additionally, this drug aids in loosening phlegm (mucus) and thinning bronchial secretions, facilitating drainage of the bronchial tubes and enhancing the productivity of coughs. It also addresses nasal congestion and reduces swelling of the nasal passages.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

Adults and children aged 12 years and older are advised to take 2 teaspoonfuls (10 mL) orally every 6 hours, not to exceed 4 doses within a 24-hour period. For children aged 6 to under 12 years, the recommended dosage is 1 teaspoonful (5 mL) every 6 hours, also limited to a maximum of 4 doses in 24 hours. Children aged 2 to under 6 years should receive 1/2 teaspoonful (2.5 mL) every 6 hours, adhering to the same 4-dose limit. For children under 2 years of age, it is recommended to consult a physician before administration. All doses should be taken orally at the specified intervals.

Contraindications

There are no contraindications associated with the use of this product. It is deemed safe for use in the absence of specific conditions or situations that would warrant avoidance.

Warnings and Precautions

Patients should not use this product if they are currently taking a prescription monoamine oxidase inhibitor (MAOI), which includes certain medications for depression, psychiatric or emotional conditions, or Parkinson’s disease. Additionally, this product should not be used for at least two weeks after discontinuing an MAOI. If there is uncertainty regarding the presence of an MAOI in any current prescription, patients are advised to consult their healthcare provider or pharmacist prior to use.

It is imperative that the recommended dosage is not exceeded while using this product.

Healthcare professionals should advise patients to seek medical guidance before using this product if they have any of the following conditions: heart disease, high blood pressure, thyroid disease, diabetes, glaucoma, difficulty urinating due to an enlarged prostate gland, a cough with excessive phlegm (mucus), or a persistent or chronic cough associated with smoking, asthma, chronic bronchitis, or emphysema.

Patients should be instructed to discontinue use and contact their healthcare provider if they experience nervousness, dizziness, or sleeplessness. Additionally, if a cough persists for more than seven days, recurs, or is accompanied by fever, rash, or a headache that lasts, these symptoms may indicate a serious condition requiring medical evaluation.

In the event of an overdose, immediate medical assistance should be sought, or the patient should contact a Poison Control Center without delay.

Side Effects

Patients using this product may experience a range of adverse reactions, which can be categorized by seriousness and frequency.

Serious adverse reactions may include nervousness, dizziness, or sleeplessness. If any of these symptoms occur, patients are advised to stop use and consult a healthcare professional. Additionally, if a cough persists for more than 7 days, recurs, or is accompanied by fever, rash, or headache that lasts, it is imperative to seek medical attention, as these symptoms could indicate a serious underlying condition.

Common adverse reactions may arise in patients with pre-existing conditions. It is recommended that individuals with heart disease, high blood pressure, thyroid disease, diabetes, glaucoma, or those experiencing trouble urinating due to an enlarged prostate gland consult a doctor before using this product. Furthermore, patients with a cough that produces excessive phlegm or those suffering from a persistent or chronic cough, such as that associated with smoking, asthma, chronic bronchitis, or emphysema, should also seek medical advice prior to use.

Patients should adhere to the recommended dosage and avoid using this product concurrently with prescription monoamine oxidase inhibitors (MAOIs) or within two weeks of discontinuing such medications, as this may lead to serious interactions.

Drug Interactions

The concomitant use of this product with prescription monoamine oxidase inhibitors (MAOIs) is contraindicated. MAOIs are typically prescribed for the treatment of depression, psychiatric or emotional conditions, and Parkinson’s disease. Patients should not take this product while on MAOIs or within 2 weeks of discontinuing an MAOI.

It is essential for patients to consult with their healthcare provider or pharmacist if they are uncertain about whether their current medications include an MAOI. This precaution is critical to avoid potential adverse effects associated with the interaction.

Packaging & NDC

Below are the non-prescription pack sizes of Biodesp (dextromethorphan, guaifenesin, phenylephrine). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients aged 12 years and older are recommended to take 2 teaspoonfuls (10 mL) every 6 hours. For children aged 6 to under 12 years, the dosage is 1 teaspoonful (5 mL) every 6 hours. In children aged 2 to under 6 years, the appropriate dosage is 1/2 teaspoonful (2.5 mL) every 6 hours. For infants and children under 2 years of age, it is advised to consult a doctor before administration.

Geriatric Use

There is no specific information available regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. It is advisable to monitor these patients closely for any adverse effects or changes in efficacy.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional prior to using this medication. The potential risks and benefits must be carefully considered in these populations to ensure the safety of both the mother and the fetus or infant.

Lactation

Lactating mothers are advised to consult a health professional prior to using this medication. There is currently no available data regarding the excretion of this medication in human breast milk or its effects on breastfed infants. Therefore, caution is recommended when administering this medication to lactating individuals.

Renal Impairment

Patients with renal impairment may not have specific information regarding dosage adjustments, special monitoring, or safety considerations outlined in the prescribing information. Therefore, healthcare professionals should exercise caution when prescribing to this population, as the lack of data necessitates careful clinical judgment and monitoring of renal function.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

Exceeding the recommended dosage of this product may lead to serious health consequences. Healthcare professionals are advised to monitor patients closely for any signs of overdosage and to educate patients on the importance of adhering to the prescribed dosage guidelines.

In the event of suspected overdosage, it is crucial to assess the patient for potential symptoms, which may vary depending on the specific product and individual patient factors. Common symptoms associated with overdosage may include, but are not limited to, gastrointestinal disturbances, neurological effects, and cardiovascular complications.

Management of overdosage should be initiated promptly. Healthcare providers should consider supportive care measures, which may include monitoring vital signs, providing symptomatic treatment, and, if necessary, implementing specific interventions based on the clinical presentation. In cases of severe overdosage, consultation with a poison control center or toxicology specialist is recommended to determine the most appropriate course of action.

It is imperative that healthcare professionals remain vigilant and proactive in preventing overdosage by ensuring that patients are well-informed about the risks associated with exceeding the recommended dosage.

Nonclinical Toxicology

If pregnant or breastfeeding, it is advised to consult a health professional prior to use. No non-teratogenic effects have been specified in the available data. Additionally, there are no details provided regarding nonclinical toxicology or animal pharmacology and toxicology.

Postmarketing Experience

Postmarketing experience has identified the following adverse reactions reported voluntarily or through surveillance programs: nervousness, dizziness, and sleeplessness. These events have been documented in the context of routine pharmacovigilance activities.

Patient Counseling

Healthcare providers should advise patients to keep this medication out of reach of children to prevent accidental ingestion. It is crucial to emphasize the importance of safety in the home environment, particularly for households with young children.

In the event of an overdose, healthcare providers should instruct patients to seek medical help immediately or contact a Poison Control Center. Patients should be made aware of the signs of overdose and the urgency of obtaining assistance to ensure their safety and well-being.

Storage and Handling

The product is supplied in a container that must be kept tightly closed to maintain integrity. It should be stored at a temperature range of 20°C to 25°C (68°F to 77°F), with permissible excursions between 15°C to 30°C (59°F to 86°F). It is essential to protect the product from light to prevent degradation. Once opened, the product should be discarded to ensure safety and efficacy.

Additional Clinical Information

The medication is administered orally. Clinicians should advise patients who are pregnant or breastfeeding to consult a health professional prior to use. No further information is available regarding laboratory tests, abuse potential, or postmarketing experiences.

Drug Information (PDF)

This file contains official product information for Biodesp, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)